tert-butyl 4-(2-(3-(2-(tert-butoxycarbonylamino)acetamido)phenyl)-5-oxo-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-yl)piperazine-1-carboxylate | 1355454-30-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl 4-(2-(3-(2-(tert-butoxycarbonylamino)acetamido)phenyl)-5-oxo-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-yl)piperazine-1-carboxylate
• 英文别名: tert-butyl 4-[2-[3-[[2-[(2-methylpropan-2-yl)oxycarbonylamino]acetyl]amino]phenyl]-5-oxo-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-yl]piperazine-1-carboxylate
• CAS: 1355454-30-6
• 化学式: C₂₇H₃₅N₇O₆S
• 分子量: 585.684
• InChiKey: CYVAMGVRBUJRHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  41
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  171
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(2-(3-(2-(tert-butoxycarbonylamino)acetamido)phenyl)-5-oxo-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-yl)piperazine-1-carboxylate 、 三氟乙酸 以 二氯甲烷 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  A novel class of ion displacement ligands as antagonists of the αIIbβ3 receptor that limit conformational reorganization of the receptor

  摘要：

  A collection of alpha IIb beta 3 integrin receptor antagonists possessing a unique MIDAS metal ion displacement mechanism of action is presented. Insight into these agents' structure- activity relationships, binding modality, and pharmacokinetic and pharmacodynamic profiles highlight the potential of these small molecule ion displacement ligands as attractive candidates for clinical development. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2013.12.122
• 作为产物：
  描述：

  5-(3-硝基苯基)[1,3,4]噻二唑-2-胺 在 1,2-二氯乙烷 、 肼 、 三氯氧磷 作用下， 以 乙醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl 4-(2-(3-(2-(tert-butoxycarbonylamino)acetamido)phenyl)-5-oxo-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-yl)piperazine-1-carboxylate
  参考文献：
  名称：

  ORGANIC COMPOUNDS

  摘要：

  本发明涉及用于抑制和/或减少血小板沉积、粘附和/或聚集的化合物和组合物。本发明还涉及用于治疗或预防血栓性疾病的方法，包括中风、心肌梗死、不稳定性心绞痛、外周血管疾病、血管成形术或支架置入后的突然闭塞以及血栓形成等。

  公开号：

  US20150374697A1

文献信息

• Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines
  申请人：Coller Barry S.

  公开号：US09066948B2

  公开（公告）日：2015-06-30

  The present invention relates to compounds of formula P-1 and related compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The definitions of A, Y, R1, R2, Ra, Ra′, Rb, Rb′, Rc, Rc′, Rd, Rd′, Re, and Re′ are provided herein. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.

  本发明涉及式P-1和相关化合物及组合物，用于抑制和/或减少血小板沉积、黏附和/或聚集。本文提供了A、Y、R1、R2、Ra、Ra'、Rb、Rb'、Rc、Rc'、Rd、Rd'、Re和Re'的定义。本发明还涉及用于治疗或预防血栓性疾病的方法，包括中风、心肌梗塞、不稳定型心绞痛、外周血管疾病、血管成形术或支架置入后的突然闭塞和血管手术引起的血栓形成。
• US9066948B2
  申请人：——

  公开号：US9066948B2

  公开（公告）日：2015-06-30
• US9532989B2
  申请人：——

  公开号：US9532989B2

  公开（公告）日：2017-01-03
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：UNIV ROCKEFELLER

  公开号：WO2012009688A1

  公开（公告）日：2012-01-19

  The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.
• A novel class of ion displacement ligands as antagonists of the αIIbβ3 receptor that limit conformational reorganization of the receptor
  作者：Jian-kang Jiang、Joshua G. McCoy、Min Shen、Christopher A. LeClair、Wenwei Huang、Ana Negri、Jihong Li、Robert Blue、Amanda Weil Harrington、Sarasija Naini、George David、Won-Seok Choi、Elisabetta Volpi、Joseph Fernandez、Mariana Babayeva、Mark A. Nedelman、Marta Filizola、Barry S. Coller、Craig J. Thomas

  DOI：10.1016/j.bmcl.2013.12.122

  日期：2014.2

  A collection of alpha IIb beta 3 integrin receptor antagonists possessing a unique MIDAS metal ion displacement mechanism of action is presented. Insight into these agents' structure- activity relationships, binding modality, and pharmacokinetic and pharmacodynamic profiles highlight the potential of these small molecule ion displacement ligands as attractive candidates for clinical development. Published by Elsevier Ltd.